Cogent Biosciences reports positive bezuclastinib results, $453 mln cash through 2027.

• Cogent Biosciences reports positive bezuclastinib trial results in NonAdvanced Systemic Mastocytosis • Achieved statistical significance across primary and key secondary endpoints • On track to share results from PEAK in GIST and APEX in AdvSM in 2H 2025 • $453 million in pro-forma cash sufficient to fund operations through 2027 • Proceeds from upsized $230 million public offering in July 2025

Cogent Biosciences, Inc. (Nasdaq: COGT) has reported positive top-line results from its SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM). The trial achieved statistical significance across all primary and key secondary endpoints, demonstrating clinically meaningful results [1].

The company's President and Chief Executive Officer, Andrew Robbins, expressed optimism about the trial's outcomes, stating, "These positive data along with the favorable safety profile give us confidence that bezuclastinib has the potential to become the new standard-of-care for NonAdvSM patients" [1].

Cogent Biosciences is on track to share pivotal trial results from PEAK in GIST and APEX in Advanced Systemic Mastocytosis (AdvSM) in the second half of 2025. The company has also announced a $453 million pro-forma cash position, sufficient to fund operations through the anticipated launch and into 2027. This funding includes proceeds from an upsized $230 million public offering in July 2025 [1].

The company's financial results for the second quarter ended June 30, 2025, showed a cash position of $237.8 million. Research and development expenses were $62.2 million, up from $54.3 million in the same period of 2024. General and administrative expenses were $13.4 million, up from $10.1 million in the same period of 2024. The company reported a net loss of $73.5 million for the second quarter of 2025, compared to $59.0 million in the same period of 2024 [1].

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The company's most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation and other mutations in KIT exon 17. The company is also developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, and KRAS [1].

References:
[1] https://finance.yahoo.com/news/cogent-biosciences-reports-recent-business-120000145.html
[2] https://www.morningstar.com/news/globe-newswire/9506094/cogent-biosciences-reports-recent-business-highlights-and-second-quarter-2025-financial-results